Edwards Lifesciences’ SAPIEN M3 becomes first FDA-approved transseptal mitral valve replacement
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The initiative is focused on a problem that continues to plague cancer outcomes in India
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
Through the use of robotic assisted orthopaedic surgeries, the success rate is close to 98%
Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
Subscribe To Our Newsletter & Stay Updated